Boxed warning

The boxed warning meaning is simple: the FDA requires its strongest label warning when a prescription drug has a serious risk or use restriction that prescribers must see. A boxed warning is not a ban or recall; the medicine can remain approved, marketed, and prescribed with the warning in place.

What is a boxed warning?

A boxed warning is prominent safety text at the beginning of a prescription drug’s full prescribing information. The FDA’s labeling guide says the box contains contraindications or warnings about serious reactions that may cause death or serious injury.

The common name is “black box warning,” so the black box warning meaning and boxed warning meaning are the same. “Boxed warning” is FDA’s term. The box tells a prescriber which risk, patient group, monitoring step, or restriction needs special attention; the rest of the label supplies the detail.

Does a boxed warning mean a drug is banned or recalled?

A boxed warning does not mean a drug is banned or recalled. The warning changes how a serious risk is communicated and managed; a recall removes or corrects a defective or potentially harmful product. The FDA defines a drug recall separately, while approved drugs with boxes can remain on pharmacy shelves and in clinical use.

That distinction matters across our regulatory status reference and side-effects guide. A box is serious, but it is not shorthand for “nobody can prescribe this.” Read what the warning says, who it applies to, and what evidence supports it.

What does semaglutide’s boxed warning actually say?

Semaglutide carries a boxed warning for thyroid C-cell tumors. The current Ozempic label says semaglutide caused dose- and treatment-duration-dependent C-cell tumors in rodents; whether that finding applies to humans has not been determined.

The label contraindicates semaglutide for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Semaglutide remains FDA-approved and prescribed. Similar thyroid C-cell tumor boxes appear on current U.S. labels for liraglutide, dulaglutide, tirzepatide, and extended-release exenatide products in the wider GLP-1 peptide family.

The useful evidence check is blunt: “boxed” describes the warning’s prominence, not the evidence tier. For semaglutide, the tumor signal is animal evidence; the label does not claim that semaglutide has been shown to cause those tumors in humans.